IVD China last week: YHLO, Sansure, Wondfo, KingMed Diagnostics

YHLO Announces World-First Breakthrough in Central Nervous System Diagnostic Testing

Recently, YHLO obtained medical device registration approval from the China Guangdong Provincial Medical Products Administration for its self-developed soluble CD146 (sCD146) detection kit based on chemiluminescence. As the first company globally to offer an sCD146 detection reagent for cerebrospinal fluid, this milestone marks a major breakthrough for YHLO in central nervous system disease diagnostics. With this approval, YHLO now has a total of 173 domestic chemiluminescence reagent products.

The translation of sCD146 from research to application not only revolutionizes the diagnostic approach for immune-mediated inflammatory demyelinating diseases of the central nervous system but also reinforces China’s international leadership in this field. It provides patients worldwide with more efficient and high-quality diagnostic solutions and represents a landmark achievement for advancing industry technology and clinical care standards. 

Sansure Biotech Partners with AliHealth to Launch Home-Based Rapid Testing

Recently, Sansure Biotech and AliHealth, a leading internet healthcare platform, officially established an exclusive partnership, with Sansure becoming the sole supplier for AliHealth’s home-based rapid respiratory testing service. Together, they launched the “12-Pathogen Respiratory Virus and Bacteria Panel,” enabling users to complete professional-grade testing at home with results available in an average of three hours, providing a scientific basis for proper medication use and effectively alleviating healthcare pressure during flu season.

As the exclusive provider for AliHealth’s home rapid testing service, Sansure Biotech brings over a decade of technical expertise in respiratory testing, combined with its end-to-end industry chain integration capabilities and early entry into the rapid testing sector since 2023. 

Wondfo Biotech and The First Affiliated Hospital of Xi’an Jiaotong University Enter Strategic Partnership

During the 16th Annual Academic Conference on Medical-Engineering Collaborative Technological Innovation of Xi’an Jiaotong University, Wondfo Biotech officially signed a strategic cooperation agreement with the hospital. Over the next five years, the two parties will jointly establish a research institute and carry out in-depth industry-academia-research collaboration, aiming to set a benchmark for hospital-enterprise collaborative innovation. As a designated national medical center, the hospital has been committed to establishing a full-chain pathway from “clinical needs → technology R&D → industrial transformation,” with the Lugang Campus serving as a core platform to expand new spaces for medical-engineering collaboration. 

The First Hospital of Jilin University and KingMed Diagnostics Establish Strategic Partnership

The First Hospital of Jilin University and KingMed Diagnostics successfully held an academic exchange meeting and signed a strategic cooperation agreement. Leveraging this partnership, the two parties will jointly establish laboratories, co-develop innovative technologies, and conduct multicenter research, building a high ground for precision medicine development and enhancing regional clinical capabilities and discipline construction.

This deepened strategic cooperation exemplifies the complementary strengths of both parties. KingMed Diagnostics will fully utilize its technical platforms and research resources to translate more scientific achievements into practical clinical technologies and services, delivering the benefits of “early detection, early diagnosis, and early treatment” to a broader patient population and contributing strongly to the development of a healthy China.